developed a pro‐phagocytic nanoparticle (SNPACALR&aCD47) system to co‐deliver anti‐CD47 and CALR.[221] Anti‐CD47 antibody could block CD47‐SIRPα to promote the macrophages to “eat” tumor cells, meanwhile the CALR can amplify the tumor‐phagocytosis of macrophages and eventually enhance the macrophage‐based cancer immunotherapy. Here, SIRPA is linked to cancer.